Preferential Initiation of Long-Acting Injectable Versus Oral HIV Pre-Exposure Prophylaxis Among Women Who Inject Drugs.
Alexis M Roth, Tyler S Bartholomew, Kathleen M Ward, Allison Groves, Silvana Mazzella, Scarlett Bellamy, K Rivet Amico, Adam W Carrico, Gail Ironson, Douglas Krakower
Author Information
Alexis M Roth: Department of Community Health and Prevention, Drexel University, Dornsife School of Public Health, Philadelphia, Pennsylvania, USA. ORCID
Tyler S Bartholomew: Department of Public Health Sciences, University of Miami Miller School of Medicine, Miami, Florida, USA.
Kathleen M Ward: Department of Community Health and Prevention, Drexel University, Dornsife School of Public Health, Philadelphia, Pennsylvania, USA.
Allison Groves: Department of Community Health and Prevention, Drexel University, Dornsife School of Public Health, Philadelphia, Pennsylvania, USA.
Silvana Mazzella: Prevention Point Philadelphia, Philadelphia, Pennsylvania, USA.
Scarlett Bellamy: Department of Biostatistics, Boston University School of Public Health, Boston, Massachusetts, USA.
K Rivet Amico: Department of Health Behavior and Health Education, University of Michigan School of Public Health, Ann Arbor, Michigan, USA.
Adam W Carrico: Department of Health Promotion and Disease Prevention, Florida International University, Robert Stempel College of Public Health and Social Work, Miami, Florida, USA.
Gail Ironson: Department of Psychology, University of Miami, Miami, Florida, USA.
Douglas Krakower: Department of Population Medicine, Harvard Medical School, Boston, Massachusetts, USA.
Fifty-five of 62 women who inject drugs (WWID) selected long-acting cabotegravir (CAB-LA) over oral PrEP, and 51/55 received a first injection. More recent injection drug use and number of sexual partners were associated with selecting CAB-LA (P < .05). Findings provide preliminary evidence of a strong preference for longer-acting products among WWID.
